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Abstract OBJECTIVES: Vandetanib¸ lenvatinib, and cabozantinib are tyrosine kinase 
inhibitors (TKIs) targeting VEGFR subtypes 1 and 2, EGFR and the RET-tyrosine 
kinase, thus considered as multiple TKIs. These TKIs have already been approved 
for treating patients suffering from thyroid cancer and renal cell carcinoma. 
Ellipticine, a DNA-damaging drug, is another anticancer agent that is effective 
against certain tumors of the thyroid gland, ovarian carcinoma, breast cancer and 
osteolytic breast cancer metastasis. Its anticancer efficiency is dictated by its oxi-
dation with cytochrome P450 (CYP) and peroxidase enzymes. A number of stud-
ies testing the effectiveness of individual anticancer drugs, the pharmacological 
efficiencies of which are affected by their metabolism, alone or in a combination 
with other cytostatics demonstrated that such combination can have both positive 
and negative effects on treatment regimen. The aim of this study was to study the 
effect of vandetanib, lenvatinib and cabozantinib on oxidation of ellipticine which 
dictates its pharmacological efficiency.
METHODS: Ellipticine oxidation catalyzed by hepatic microsomes, recombinant 
CYP enzymes and peroxidases (horseradish peroxidase, lactoperoxidase and 
myeloperoxidase) and the effect of TKIs (vandetanib, lenvatinib and cabozan-
tinib) on this oxidation were analyzed by HPLC used for separation of ellipticine 
metabolites and quantification of their amounts formed during oxidation.
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RESULTS: The CYP enzymatic system oxidizes ellipti-
cine up to five metabolites (9-hydroxy-, 12-hydroxy-, 
13-hydroxy-, 7-hydroxyellipticine, and ellipticine 
N2- oxide), while peroxidases form predominantly 
ellipticine dimer. Ellipticine oxidation catalyzed by rat 
and human hepatic microsomes was inhibited by van-
detanib and cabozantinib, but essentially no inhibition 
was caused by lenvatinib. Of individual CYP enzymes 
catalyzing oxidation of ellipticine, TKIs inhibited 
oxidation of ellipticine catalyzed by CYP2D6 > 2D1 > 
2C9 > 3A1 > 3A4, the CYP enzymes participating in 
ellipticine oxidation to metabolites increasing the ellip-
ticine anticancer efficiency. On the contrary, they have 
essentially no inhibition effect on ellipticine oxidation 
catalyzed by CYP1A1 and 1A2, which are the enzymes 
that predominantly detoxify this drug. All tested TKIs 
had essentially no effect on oxidation of ellipticine by 
used peroxidases.
CONCLUSION: The results found demonstrate that 
TKIs vandetanib, lenvatinib and cabozantinib cause a 
decrease in oxidative activation of DNA-damaging drug 
ellipticine by several CYP enzymes in vitro which might 
lead to a decrease in its pharmacological efficiency. In 
contrast, they practically do not influence its detoxifica-
tion catalyzed by CYP1A1, 1A2 and peroxidases. The 
present study indicates that tested TKIs seem not to 
have a potency to increase ellipticine anticancer effi-
ciency.
Abbreviations:
CYP  - cytochrome P450
DMSO  - dimethyl sulfoxide
HRP  - horseradish peroxidase 
EGFR  - epidermal growth factor receptor 
LPO  - lactoperoxidase
MPO  - myeloperoxidase
ND  - not determined 
NQ  - not quantified
RET  - rearranged during transfection protooncogene
r.t.  - retention time
TK  - tyrosine kinase
TKI  - tyrosine kinase inhibitor
VEGFR  - vascular endothelial growth factor receptor
INTRODUCTION
Cancer treatment is one of the most difficult problems 
in clinic practice. The drugs utilized for cancer che-
motherapy have usually a narrow therapeutic index, 
and often the produced responses are only palliative as 
well as unpredictable. Namely, although the drugs are 
directed toward certain biomacromolecules, they do 
not discriminate between rapidly dividing tumor vs. 
non-malignant cells (Heger et al. 2013). In contrast, tar-
geted therapy that has been introduced in recent years 
is directed against cancer-specific targets and signaling 
pathways, and thus provides more limited nonspecific 
mechanisms (Arora & Scholar 2005). One of the most 
promising targets are receptor tyrosine kinases (TKs), 
the enzymes that selectively phosphorylate the hydroxyl 
moieties of tyrosine residues on signal transduction 
molecules with a phosphate moiety from adenosine 
triphosphate (Reibenwein & Krainer 2008; Hartmann 
et al. 2009). Vandetanib, lenvatinib and cabozantinib 
are tyrosine kinase inhibitors (TKIs) targeting vascular 
endothelial growth factor receptor (VEGFR) subtypes 
1 and 2, epidermal growth factor receptor (EGFR) and 
the RET (rearranged during transfection)-tyrosine 
kinase, thus considered as multiple TKIs. These TKIs 
have already been approved for treating patients suffer-
ing from thyroid cancer and renal cell carcinoma, and 
further clinical trials are ongoing for prostate cancer 
and glioblastoma multiforme (Greenhill 2017; Roviello 
et al. 2018; Abdelaziz & Vaishampayan 2017).
Ellipticine (Figure 1) and its derivatives are other 
anticancer agents that are effective against certain 
tumors of the thyroid gland (anaplastic thyroid car-
cinoma, medullary thyroid carcinoma), ovarian car-
cinoma, breast cancer and osteolytic breast cancer 
metastasis (Stiborova et al. 2001; 2011; Kumarasamy 
& Sun 2017). The predominant mechanisms of ellipti-
cine’s biological effects were suggested to be (i) interca-
lation into DNA (Garbett & Graves 2004; Tmejova et al. 
2014) and (ii) inhibition of topoisomerase II (Garbett 
& Graves 2004; Stiborova et al. 2011; Kizek et al. 2012; 
Stiborova & Frei 2014). Further, ellipticine anticancer 
efficiencies are dependent on its metabolism lead-
ing both to the activation metabolites causing DNA 
damage (covalent DNA adducts) and their detoxifica-
tion to products that are excreted. Ellipticine is oxidized 
by microsomal cytochrome P450 (CYP) enzymes and 
peroxidases. Its oxidative activation by CYP3A, 2C and 
2D leads to formation of 12-hydroxy- and 13-hydroxy-
ellipticine, reactive metabolites that are converted to 
ellipticine-12-ylium and ellipticine-13-ylium, binding 
to DNA, while formation 9-hydroxyellipticine and the 
ellipticine dimer catalyzed by CYP1A1/2 and peroxi-
dases, respectively, are considered to be detoxification 
pathway of its metabolism (Figure 1) (Stiborova et al. 
2004; 2011; Stiborova & Frei 2014).
Overall, in cancer chemotherapy, serious clinical 
consequences may occur from small alterations in drug 
metabolism affecting drug pharmacokinetics. Such 
alterations might be caused by several reasons, of them 
the drug-drug interactions influencing their metabo-
lism might be one of most important. A number of 
studies testing the effectiveness of individual anticancer 
drugs alone or in a combination with other cytostatics 
demonstrated that such combination can have addi-
tive and/or contradictory effects on treatment regimen 
(for a review, see Stiborova et al. 2012a). In this con-
text, ellipticine anticancer effects have been found to 
be increased by another drug, an histone deacetylase 
inhibitor valproic acid (VPA), which is mediated by 
its influence on ellipticine metabolism (Poljakova et 
al. 2011; Cerna et al. 2018). The aim of this study was 
to investigate the effect of additional anticancer drugs, 
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TKIs vandetanib, lenvatinib and cabozantinib, namely, 
their effects on oxidative metabolism of ellipticine dic-
tating its pharmacological efficiency.
MATERIALS AND METHODS
Chemicals and material 
Vandetanib, lenvatinib and cabozantinib were from 
LC Laboratories (Woburn, MA, USA), ellipticine, 
NADPH, horseradish peroxidase (HRP) type VI, 
bovine lactoperoxidase (LPO), human myeloperoxi-
dase (MPO) and other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO, USA) in ACS purity 
(purity meets the standards of American Chemical 
Society), unless noted otherwise. Rat microsomes were 
isolated from liver of male rats (Wistar) as described 
previously (Stiborova et al. 2001). Male human hepatic 
microsomes (pooled sample) (sample LOT: 3043885), 
were from Gentest Corp. (Woburn, MA, USA). Human 
and rat recombinant enzymes were used in the forms 
Fig. 1. Scheme of ellipticine metabolism catalyzed by CYPs and peroxidases showing the identified metabolites and 
those proposed to form DNA adducts. The compounds showed in brackets were not detected under the experimental 
conditions and/or not yet structurally characterized. The CYP enzymes predominantly oxidizing ellipticine shown in the 
figure were identified in our previous studies (Stiborova et al. 2004; 2008; 2012b; Kotrbova et al. 2011). 
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When the effect of TKIs vandetanib, lenvatinib and 
cabozantinib was investigated, the incubation mixtures 
also contained 10 μM TKIs dissolved in 1μl DMSO. All 
reactions were initiated by adding ellipticine dissolved 
in DMSO. Control incubations were either without 
peroxidases, or without hydrogen peroxide, or without 
TKIs, or without ellipticine. Incubations were carried 
out at 37°C for 15 min. After incubations, 5 μl of 1 mM 
of phenacetine in methanol was added as an internal 
standard, and the ellipticine metabolites were extracted 
twice with ethyl acetate (2×1 ml) as described (Stiborova 
et al. 2007). The extracts were evaporated and dissolved 
in 50 μl of methanol. Ellipticine and its metabolites 
were separated by HPLC. The column used was a 5 μm 
Ultrasphere ODS (Beckman, 4.6×250 mm) preceded by 
a C-18 guard column. The eluents were 45–90% metha-
nol in 10 mM ammonium acetate (pH 2.8), with flow 
rate of 0.8 ml/min, detection was at 296 nm (Stiborova 
et al. 2004; 2007; Poljakova et al. 2005). Recoveries of 
ellipticine metabolites were around 95% in the presence 
of enzymes without hydrogen peroxide. One product 
peak with r.t. of 16.0 min and unconverted ellipticine 
with r.t. of 11.8 min were separated by HPLC. The ellip-
ticine metabolite was identified by mass spectroscopy, 
NMR and/or cochromatography on HPLC to be ellip-
ticine dimer as described previously (Stiborova et al. 
2007).
Statistical analyses
For statistical data analysis we used Student’s t-test. All 
p-values are two-tailed and considered significant at the 
0.05 level. 
RESULTS AND DISCUSSION
The effect of vandetanib, lenvatinib and cabozantinib on 
ellipticine oxidation catalyzed by rat and human hepatic 
microsomes
In the study, liver microsomes of rats and humans 
were used as model in vitro systems, because rats have 
been shown to mimic the metabolism of ellipticine in 
humans, and the liver rich in enzymes biotransform-
ing xenobiotics including drugs is the major organ 
responsible for metabolism of these chemicals (Sti-
borova et al. 2006; Stiborova & Frei 2014). Ellipticine 
was oxidized by rat and human hepatic microsomes 
up to three metabolites (9-hydroxy-, 12-hydroxy- and 
13-hydroxyellipticine) (Figure 2) that were separated by 
HPLC (see insert in Figure 2A). Other two metabolites 
(7-hydroxyellipticine and ellipticine N2-oxide) (Stibo-
rova et al. 2004; 2006) were formed at very low amounts 
(if any) and, therefore, they were not quantified (NQ) 
(Figure 2).
Of ellipticine reaction products formed in the sys-
tems, 9-hydroxyellipticine is considered as a detoxifi-
cation metabolic product, whereas 12-hydroxy- and 
13-hydroxyellipticine are the activation metabolites 
participating in an increase in ellipticine antican-
of Supersomes™ that are microsomes isolated from 
insect cells transfected with a baculovirus construct 
containing cDNA of human and rat CYP enzymes 
(CYP1A1, 1A2, 2C9, 2D1/6, 3A1/4), and which also 
express NADPH:CYP oxidoreductase (POR) and/or 
cytochrome b5. They were purchased from Gentest 
Corp. (Woburn, MA, USA).
Oxidation of ellipticine by hepatic microsomes and CYP 
enzymes and the effect of TKIs on this oxidation
Unless stated otherwise, incubation mixtures used to 
study ellipticine metabolism contained the following in 
a final volume of 500 μl: 100 mM potassium phosphate 
buffer (pH 7.4), 1 mM NADPH, rat or human hepatic 
microsomes (0.25 mg protein), or rat or human recom-
binant CYPs in Supersomes™ (50 pmol) and 50 μM 
ellipticine dissolved in 5 μl dimethyl sulfoxide (DMSO). 
When the effect of TKIs vandetanib, lenvatinib and 
cabozantinib was investigated, the incubation mixtures 
also contained 50 μM TKIs dissolved in 5 μl DMSO. The 
reaction was initiated by adding ellipticine. In the con-
trol incubations, either microsomes or CYP or NADPH 
or TKIs or ellipticine were omitted. After incubation 
at 37 °C for 20 min in open plastic Eppendorf tubes 
(ellipticine oxidation was linear up to 30 min of incuba-
tion (Kotrbova et al. 2006; Stiborova et al. 2006)) and 
5 μl of 1 mM phenacetine in methanol was added as an 
internal standard, the reaction was stopped by extrac-
tion with ethyl acetate (twice with ethyl acetate, 2×1 
ml). The extracts were evaporated, dissolved in 50 μl 
of methanol and ellipticine and its metabolites were 
separated by HPLC (5 mm Ultrasphere ODS Beckman, 
4.6×250 mm preceded by a C-18 guard column); the 
eluent was 64% methanol plus 36% of 5 mM heptane 
sulfonic acid in 32 mM acetic acid in water with a flow 
rate of 0.7 ml/min, detection was at 296 nm. Ellipticine 
metabolites eluted by HPLC were characterized by mass 
spectroscopy and/or NMR as described (Stiborova et al. 
2004; 2006). Up to five ellipticine metabolites with the 
retention times of 5.8, 6.0, 6.8, 7.0 and 9.9 min, cor-
responding to 9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 
7-hydroxyellipticine and ellipticine N2-oxide, were 
separated (Stiborova et al. 2004; 2006). Recoveries of 
ellipticine metabolites were approximately 95%. In the 
incubation mixture containing lenvatinib, one broad 
peak of this TKI eluting with a retention time (r.t.) of 
5.8 min overlapped the peaks of 9-hydroxy- and/or 
12-hydroxyellipticine. Therefore, their amounts could 
not been evaluated (determined).
Oxidation of ellipticine by peroxidases and the effect of 
TKIs on this oxidation
Incubation mixtures used to evaluate the oxidation of 
ellipticine by the studied peroxidases (HRP, LPO and 
MPO), in a final volume of 500 μl, consisted of 100 mM 
potassium phosphate buffer (pH 7.4), 10 μM ellipticine 
(dissolved in 1 μl DMSO), 1, 2 or 2 μg of HRP, LPO 
or MPO, respectively, and 50 μM hydrogen peroxide. 
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cer efficiency due to the formation of covalent DNA 
adducts (Stiborova et al. 2011; Stiborova & Frei 2014). 
The same HPLC method utilized for separation of 
ellipticine metabolites was also used to examine the 
effect of TKIs on ellipticine oxidation. Vandetanib and 
cabozantinib were eluted from the HPLC column at 
retention times different from those of ellipticine and 
its metabolites (data not shown). However, lenvatinib 
was eluted as a broad peak at retention time of 5.8 min, 
frequently overlapping the peaks of 9-hydroxy- and/or 
12-hydroxyellipticine (see insert in Figure 2B). There-
fore, formation of these metabolites could not been 
determined (ND). Formation of several ellipticine 
metabolites in these microsomal systems was inhib-
ited by the tested TKIs. Oxidation of ellipticine to its 
metabolites (9-hydroxy-, 12-hydroxy- and 13-hydroxy-
ellipticine) by rat hepatic microsomes was inhibited by 
vandetanib and cabozantinib, while lenvatinib had no 
effect on ellipticine oxidation to 13-hydroxyellipticine 
catalyzed by this rat enzymatic system (Figure 2A). In 
the case of human hepatic microsomes, tested TKIs did 
not inhibit the formation of an ellipticine detoxification 
product 9-hydroxyellipticine, while except of lenvatinib, 
they inhibited formation of the activation metabolites 
12-hydroxy- and 13-hydroxyellipticine. In contrast, a 
slight, but non-significant (p=0.1) increase in ellipti-
cine oxidation to 13-hydroxyellipticine was produced 
by lenvatinib in human microsomes (Figure 2B). 
The effect of vandetanib, lenvatinib and cabozantinib on 
ellipticine oxidation catalyzed by rat and human recom-
binant CYPs
In order to evaluate the impact of TKIs on inhibition 
of ellipticine oxidation catalyzed by individual micro-
somal CYP enzymes, we investigated their effects on 
ellipticine oxidation by several CYP enzymes, espe-
cially those, which are known to be essential for its oxi-
dation. Namely, again the CYPs important both for its 
oxidative detoxification to metabolites that are excreted 
from the body and for its activation to reactive metabo-
lites responsible of formation of covalent DNA adducts 
leading to higher ellipticine anticancer efficiencies (for 
a review, see Stiborova et al. 2011; Stiborova & Frei 
2014). For such a study, rat and human recombinant 
Fig. 2. Oxidation of ellipticine by rat (A) 
and human (B) hepatic microsomes 
and the effect of vandetanib, 
lenvatinib and cabozantinib on this 
oxidation. The data are averages 
and standard deviations of three 
experiments. ***p<0.001; **p<0.01; 
*p<0.05 (Student’s t-test), levels 
of ellipticine metabolites in the 
presence of TKIs significantly 
different from those generated 
without these inhibitors. NQ – not 
quantified, ND – not determined. 
Insert in 2A shows HPLC of 
ellipticine metabolites formed 
by rat hepatic microsmes. Insert 
in 2B shows HPLC of ellipticine 
metabolites formed by human 
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CYPs were utilized. Of the CYP enzymes predomi-
nantly oxidizing ellipticine, rat and human CYP1A1/2 
which mainly detoxify ellipticine, and human CYP2C9, 
rat CYP2D1 and its human orthologue CYP2D6, and 
rat CYP3A1 and its human orthologue CYP3A4, the 
enzymes which activate ellipticine to more reactive 
metabolites, were employed. Depending on individual 
CYPs, they oxidized ellipticine up to five metabolites, 
9-hydroxy-, 12-hydroxy-, 13-hydroxy-, 7-hydroxyellip-
ticine, and ellipticine N2-oxide (Figures 3 and 4). 
Of the used CYPs, TKIs had essentially no inhibitory 
effect on ellipticine oxidation catalyzed by CYP1A1 
and 1A2. These CYPs oxidized ellipticine up to four 
metabolites, 9-hydroxy-, 12-hydroxy-, 13-hydroxy- and 
7-hydroxyellipticine, while no ellipticine N2-oxide was 
detectable (Figure 3). In contrast to no inhibition of 
ellipticine oxidation mediated by CYP1A1 and 1A2, 
an increase in levels of CYP1A1-mediated formation 
of 9-hydroxyellipticine and 7-hydroxyellipticine was 
mediated by cabozantinib (Figure 3A). In the case of 
Fig. 3. Oxidation of ellipticine by rat (A) and human (B) CYP1A1, rat (C) and human CYP1A2 (D) and the effect of vandetanib, lenvatinib 
and cabozantinib on this oxidation. The data are averages and standard deviations of three experiments. ***p<0.001; **p<0.01; *p<0.05 
(Student’s t-test), levels of ellipticine metabolites in the presence of TKIs significantly different from those generated without these 





human CYP1A1, this TKI (cabozantinib) also stimu-
lated oxidation of ellipticine to 12-hydroxyellipticine, 
while lenvatinib increased the formation of 13-hydroxy-
ellipticine (Figure 3B). Oxidation of ellipticine by rat 
CYP1A2 also resulted in formation of low amounts of 
7-hydroxyellipticine, formation of which was increased 
by vandetanib and cabozantinib during reactions cata-
lyzed by rat CYP1A2. Cabozantinib also stimulated 
oxidation of ellipticine to 9-hydroxyellipticine in this 
rat enzymatic system (Figure 3C). TKIs did not inhibit 
any of the ellipticine metabolites formed by human 
CYP1A2. Of note, 12-hydroxyellipticine is formed at 
very low amounts by this human CYP (CY1A2), and 
therefore, it was not quantified (Figure 3D). 
In contrast to CYP1A1 and 1A2, TKIs inhibited oxi-
dation of ellipticine catalyzed by CYP2D6 > 2D1 > 2C9 
> 3A1 > 3A4, the CYP enzymes participating in ellipti-
cine oxidation to metabolites increasing the ellipticine 
anticancer efficiency (Figures 3 and 4). Concerning the 
degree of inhibition effects of TKIs on these ellipticine 
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metabolites, the formation of ellipticine N2-oxide pre-
dominantly catalyzed by human CYP2D6 (Figure 4), 
which is also the major enzyme forming this ellipticine 
metabolite, was the most prominent inhibition caused 
by all analyzed TKIs. This human CYP (CYP2D6) and 
its rat orthologue (CYP2D1) did not oxidize ellipti-
cine to 7-hydroxyellipticine (Figure 4). The ellipticine 
N2-oxide is the important activation metabolic product, 
because it forms 12-hydroxyellipticine (by Polonowski 
rearrangement) (Stiborova et al. 2004), which finally 
Fig. 4. Oxidation of ellipticine by human CYP2C9 in the presence of cytochrome b5 (A), rat CYP2D1 (B), human CYP2D6 (C), rat CYP3A1 in 
the presence of cytochrome b5 (D), human CYP3A4 without (E) and in the presence of cytochrome b5 (F) and the effect of vandetanib, 
lenvatinib and cabozantinib on this oxidation. The data are averages and standard deviations of three experiments. ***p<0.001; *p<0.01; 
*p<0.05 (Student’s t-test), levels of ellipticine metabolites in the presence of TKIs significantly different from those generated without 
these inhibitors. NQ – not quantified, ND – not determined.
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forms ellipticine-12-ylium generating DNA adducts 
(Figure 1). Its formation by CYP2D1 was also inhib-
ited by TKIs, but to a lower extent. On the contrary, no 
inhibition of production of this metabolite catalyzed 
by CYP3A4 (in the presence of cytochrome b5) was 
observed (Figure 4F). 
Another activation metabolite, 12-hydroxyellipti-
cine, formed by most analyzed CYPs was not inhib-
ited by tested TKIs. This is unexpected finding when 
we compare the results showing the inhibition of 
12-hydroxyellipticine formation in hepatic micro-
somes; a decrease in amounts of this metabolite formed 
in microsomes was produced by TKIs (see Figure 2). 
We can speculate that this observed inhibition of 
12-hydroxyellipticine formation (catalyzed by many 
CYPs in hepatic microsomes and also rearranged from 
ellipticine-12-ylium) might result from inhibition of 
its primarily formed ellipticine N2-oxide that therefore 
cannot be rearranged to 12-hydroxyellipticine and thus 
also not inhibited. This suggestion needs, however, to 
be investigated in further studies. 
Oxidation of ellipticine to 13-hydroxyellipticine, the 
most important activation metabolite generating DNA 
adducts, was inhibited by lenvatinib in the enzymatic 
system of CYP3A4 and by all TKIs in the system of 
CYP3A1. But inhibition of 13-hydroxyellipticine for-
mation catalyzed by the CYP3A1 mediated by vande-
tanib and lenvatinib was not significant (p=0.06 and 
p=0.08, respectively) (Figure 4). The CYP3A enzymes 
oxidized ellipticine up to four metabolites, 13-hydroxy-
ellipticine being the predominant oxidation product. 
Whereas 9-hydroxy-, 12-hydroxy-, 13-hydroxyellip-
ticine are formed by CYP3A1, the human orthologue 
CYP3A4 can also generate ellipticine N2-oxide, but 
only when cytochrome b5 is present in the reac-
tion mixture. No 7-hydroxyellipticine was formed by 
CYP3A1/4 (Figures 4D–F). The found results indicate 
that inhibition of 13-hydroxyellipticine formation in 
hepatic microsomes by vandetanib and cabozantinib 
might be attributed to CYP3A enzymes. However, no 
inhibition of 13-hydroxyellipticine formation by len-
vatinib, found in both used subcellular enzymatic sys-
tems (rat and human hepatic microsomes) indicates 
that the situation in these microsomal systems is more 
complex. Now, we can only speculate on the reasons 
of these results. One of them can be the influence of 
lenvatinib on 13-hydroxyellipticine formation cata-
lyzed by CYP1A1 that stimulates 13-hydroxyellipticine 
formation; namely, cytochrome b5 that is the heme pro-
tein highly expressed in hepatic microsomal system is 
known to increase the CYP1A1-mediated formation of 
13-hydroxyellipticine in microsomes (Kotrbova et al. 
2011; Stiborova et al. 2012b). This feature might par-
tially compensate the inhibition of its formation caused 
by other CYP enzymes in microsomes. However again, 
such suggestion needs to be evaluated in future study.
The effect of vandetanib, lenvatinib and cabozantinib on 
ellipticine oxidation catalyzed by peroxidases
Oxidation of ellipticine to its major metabolite formed 
by peroxidases HRP, LPO and MPO, ellipticine dimer, 
which is considered to be a detoxification reaction 
product of peroxidase-mediated ellipticine oxidation 
(Stiborova et al. 2007), was utilized to investigate the 
Fig. 5. Oxidation of ellipticine by HRP (A), LPO B) and MPO (C) to 
ellipticine dimer and the effect of vandetanib, lenvatinib and 
cabozantinib on this oxidation. The data are averages and 
standard deviations of three experiments. ***p<0.001; **p<0.01; 
*p<0.05 (Student’s t-test), levels of ellipticine metabolites in the 
presence of TKIs significantly different from those generated 
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effect of TKIs on reaction catalyzed by peroxidases. All 
tested peroxidases oxidized ellipticine to this metabo-
lite, but to a different extent (Figure 5). The tested TKIs 
had essentially no effect on formation of ellipticine 
dimer catalyzed by these peroxidases; only cabozan-
tinib slightly increased oxidation of ellipticine by HRP 
while lenvatinib slightly inhibited the reaction cata-
lyzed by LPO. 
CONCLUSIONS
The results of this study demonstrate that oxidation of 
anticancer drug ellipticine mediated by CYP enzymes 
expressed in rat and human hepatic microsomal subcel-
lular fractions, which determines its pharmacological 
(anticancer) efficiencies, is influenced by TKIs vande-
tanib, lenvatinib and cabozantinib. The combination 
effects of ellipticine with tested TKIs were investigated, 
because they are the drugs utilized for treatment of thy-
roid gland cancer, exhibiting specific efficiencies to the 
individual types of this cancer (Reibenwein et al. 2008; 
Hartmann et al. 2009; Stiborova and Frei 2014). But, 
they act by different mechanisms; the DNA is target 
for ellipticine action, while TKIs regulate signaling of 
their enzymatic targets, TKs (Greenhill 2017; Roviello 
et al. 2018; Abdelaziz & Vaishampayan 2017). What is 
however not known is whether they can influence the 
anticancer potency of them. Especially, it is not known 
whether TKIs can affect the metabolism of ellipticine, 
which dictate its DNA-damaging efficiency, thereby 
modulating its therapeutic effects when administered 
in combinations. 
The data found demonstrate that TKIs vandetanib, 
lenvatinib and cabozantinib inhibit the in vitro oxida-
tive activation of ellipticine catalyzed by several CYP 
enzymes and hepatic subcellular systems expressing 
these enzymes, which might lead to a decrease in ellip-
ticine anticancer efficiency. In contrast, they practi-
cally do not influence its detoxification catalyzed by 
CYP1A1, 1A2 and peroxidases. All these results suggest 
that the TKIs might decrease the ellipticine-DNA-dam-
aging effect mediated by the tested enzymes, thereby 
being ineffective to increase ellipticine anticancer 
efficiency. The vice versa effects, namely the influence 
of ellipticine on enzyme-mediated metabolism of the 
tested TKIs, which has not been unfortunately studied 
in details as yet (Martin et al. 2012; Lacy et al. 2015; 
Nguyen et al. 2015; Shumaker et al. 2015; Dubbelman et 
al. 2016), are the challenge of our future research. 
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